Results for raf translation from Icelandic to English

raf
amber

dabrafenib er raf-kínasahemill.
dabrafenib is an inhibitor of raf kinases.

dabrafenib er hemill á raf kínasa.
dabrafenib is an inhibitor of raf kinases.

Öflun öruggra gagna um raf- og rafeindatækjasorp
tracking down good data on electric and electronic waste

tafla 5 kínasahamlandi virkni dabrafenibs gegn raf-kínösum
table 5 kinase inhibitory activity of dabrafenib against raf kinases

trametinib og dabrafenib hamla tveimur kínösum í þessum ferli, mek og raf og þar með veitir samsetning þeirra samhliða hömlun á ferilinn.
thus, trametinib and dabrafenib inhibit two kinases in this pathway, mek and raf, and therefore the combination provides concomitant inhibition of the pathway.

Æxlisvaldandi stökkbreytingar á braf leiða til óskilyrtrar virkjunar á ras/raf/mek/erk ferlinum.
oncogenic mutations in braf lead to constitutive activation of the ras/raf/mek/erk pathway.

Æxlismyndandi stökkbreytingar á braf valda óskilyrtri virkjun ras/raf/mek/erk-ferilsins.
oncogenic mutations in braf lead to constitutive activation of the ras/raf/mek/erk pathway.

regorafenib er æxlishemjandi lyf til inntöku, sem er öflugur hemill fyrir ýmsa próteinkínasa, þ.m.t. kínasa sem taka þátt í nýmyndun æða í æxlum (vegfr1, -2, -3, tie2), myndun krabbameins (kit, ret, raf-1, braf, brafv600e) og mótun innri aðstæðna í æxlum (tumour microenvironment) (pdgfr, fgfr).
regorafenib is an oral tumour deactivation agent that potently blocks multiple protein kinases, including kinases involved in tumour angiogenesis (vegfr1, -2, -3, tie2), oncogenesis (kit, ret, raf-1, braf, brafv600e), and the tumour microenvironment (pdgfr, fgfr).